(Q43415576)

23 November 2017

title

α-Defensins and outcome in patients with chronic heart failure (English)

1 reference

23 November 2017

1 reference

chronic heart failure

1 reference

9

1 reference

23 November 2017

5

Allan Flyvbjerg

1 reference

23 November 2017

Heidi M Christensen

1

1 reference

23 November 2017

Jan Frystyk

2

1 reference

23 November 2017

Jens Faber

3

1 reference

23 November 2017

Morten Schou

4

1 reference

23 November 2017

Per Hildebrandt

6

1 reference

23 November 2017

Ilan Raymond

7

1 reference

23 November 2017

Tobias W Klausen

8

1 reference

23 November 2017

publication date

22 February 2012

1 reference

European Journal of Heart Failure

23 November 2017

published in

1 reference

23 November 2017

volume

14

1 reference

23 November 2017

issue

4

1 reference

23 November 2017

page(s)

387-394

1 reference

The role of monocytes and inflammation in the pathophysiology of heart failure

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Defensins: antimicrobial peptides of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Defensins and cathelicidins: neutrophil peptides with roles in inflammation, hyperlipidemia and atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Human antimicrobial peptides: defensins, cathelicidins and histatins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Mammalian defensins in the antimicrobial immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

alpha-Defensin: link between inflammation and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Inflammation and metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Antithrombotic therapy for heart failure in sinus rhythm

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Multimarker approach for heart failure management: perspectives and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Defensin Modulates Tissue-type Plasminogen Activator and Plasminogen Binding to Fibrin and Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Leukocyte count and coronary heart disease: implications for risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Urinary N-terminal prohormone brain natriuretic peptide excretion in patients with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURJHF%2FHFS021

21 January 2018

Identifiers

DOI

10.1093/EURJHF/HFS021

1 reference

23 November 2017

1 reference